JCJunxing Chen

Junxing Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junxing Chen has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Information from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

    by Jinwen Liu, Gaowei Huang, Hao Lin, Rui Yang, Wenhao Zhan, Cheng Luo, Yukun Wu, Lingwu Chen, Xiaopeng Mao, Junxing Chen, et al.

    Figure S1-S17,Table S1-S2,Supplementary methods

  • Open Access

    Supplementary Data 1 from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

    by Jinwen Liu, Gaowei Huang, Hao Lin, Rui Yang, Wenhao Zhan, Cheng Luo, Yukun Wu, Lingwu Chen, Xiaopeng Mao, Junxing Chen, et al.

    Sunitinib resistant cell RNA_seq data

  • Open Access

    Supplementary Data 2 from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

    by Jinwen Liu, Gaowei Huang, Hao Lin, Rui Yang, Wenhao Zhan, Cheng Luo, Yukun Wu, Lingwu Chen, Xiaopeng Mao, Junxing Chen, et al.

  • Open Access

    Data from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

    by Jinwen Liu, Gaowei Huang, Hao Lin, Rui Yang, Wenhao Zhan, Cheng Luo, Yukun Wu, Lingwu Chen, Xiaopeng Mao, Junxing Chen, et al.

    Sunitinib is a first-line targeted therapy for patients with renal cell carcinoma (RCC), but resistance represents a significant obstacle to the treatment of advanced and metastatic RCC. Metabolic reprogramming is a characteristic of RCC, and changes in metabolic processes might contribute to resistance to sunitinib. In this study, we identified methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a mitochondrial enzyme involved in one-carbon metabolism, as a critical mediator of sunitinib resistance in RCC. MTHFD2 was elevated in sunitinib-resistant RCC cells, and loss of MTHDF2 conferred sensitivity to sunitinib. In patients, MTHFD2 was highly expressed in RCC and was associated with poor outcomes. Mechanistically, MTHFD2 stimulated UDP-N-acetylglucosamine (UDP-GlcNAc) biosynthesis and promoted cMYC O-GlcNAcylation by driving the folate cycle. O-GlcNAcylation enhanced cMYC stability and promoted MTHFD2 and cyclin D1 transcription. Targeting MTHFD2 or cyclin D1 sensitized tumor cells to sunitinib in vitro and in vivo. Consistently, development of a peptide drug capable of efficiently degrading MTHFD2 enabled reversal of sunitinib resistance in RCC. These findings identify a noncanonical metabolic function of MTHFD2 in cell signaling and response to therapy and reveal the interplay between one-carbon metabolism and sunitinib resistance in RCC. Targeting MTHFD2 could be an effective approach to overcome sunitinib resistance.Significance:MTHFD2 regulates cMYC O-GlcNAcylation to promote sunitinib resistance in renal cell carcinoma, highlighting the important role of one-carbon metabolism in sunitinib resistance and proposing therapeutic strategies to improve patient outcomes.

  • Open Access

    Evaluation of human epidermal growth factor receptor 2 (HER2)-related genes revealed that HER2-antibody-drug conjugate (ADC) drugs confer clinical benefits to Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer patients

    by Wenhao Zhan, Dongxin An, Jiahao Lei, Hiocheng Un, Renxuan Lin, Junxing Chen, Ren Liu, Zongren Wang

    Current guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) instillation as the first-line treatment for high-risk non-muscle invasive bladder cancer (HR-NMIBC). However, a substantial proportion of BCG-refractory patients progress to muscle-invasive bladder cancer (BCa), and effective bladder-sparing therapeutic options remain scarce for this population. This study aims to develop a transcriptome-based predictive model for identifying HR-NMIBC patients who may benefit from human epidermal growth factor receptor 2 (HER2)-targeted therapy following BCG treatment failure, and to validate its clinical feasibility. We conducted a retrospective analysis of HR-NMIBC cases treated with BCG over the past decade at our institution to investigate the association between HER2 expression and clinical outcomes. Public databases were interrogated to elucidate the mechanisms underlying BCG failure in HER2-overexpressing NMIBC. A HER2-related prognostic score (HRS) model was developed using bioinformatics approaches, with subsequent exploration of transcriptomic disparities between high-risk and low-risk subgroups. The therapeutic potential of HER2-targeted agents was further validated through in vitro experiments using human BCa cell lines and in vivo murine orthotopic BCa models. Real-world retrospective analysis revealed HER2 overexpression as an independent predictor of BCG failure in NMIBC patients. The HRS prognostic model, constructed through Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression analysis of HER2-high versus HER2-low subgroups, demonstrated superior clinical outcomes for low-risk patients via Kaplan-Meier analysis. Progression-free survival-time-dependent-receiver operating characteristic (PFS-time-dependent-ROC) curves exhibited robust sensitivity and specificity at 1-, 3-, and 5-year intervals. Preclinical validations in cellular and animal models showed promising therapeutic efficacy of HER2-targeted interventions. HER2 overexpression serves as an independent prognostic biomarker for BCG failure in HR-NMIBC. The HRS prognostic model effectively stratifies high-risk patients who may derive clinical benefit from HER2-targeted therapeutic strategies.

  • Open Access

    Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer

    by Guan-Kai Huang, Xin-Xin Zhang, Lin-Yuan Huang, Hio-Cheng Un, Ren-Xuan Lin, Jun-Xing Chen, Zong-Ren Wang, Ling-Li Long

    Background: Bladder cancer (BCa) is one of the most prevalent urological malignancies globally with substantial clinical challenges characterized by high recurrence rates and limited treatment options for advanced disease. Although immune checkpoint inhibitors (ICIs) provide clinical benefit, their efficacy is restricted, with objective response rates of only 20–25%. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown remarkable success in other solid tumors but remains largely unexplored in BCa. The emergence of patient-derived organoids (PDO) offers a physiologically relevant ex vivo platform for functionally evaluating TIL by preserving tumor heterogeneity. Methods: TIL were isolated from BCa patient specimens and robustly expanded ex vivo using interleukin-2 (IL-2) and a rapid expansion protocol (REP). Expansion efficiency was quantified, and TIL phenotypes were characterized via flow cytometry. Transcriptional and clonal dynamics were profiled using single-cell RNA sequencing (scRNA-seq) coupled with T-cell receptor (TCR) sequencing. The anti-tumor efficacy of TIL, both as monotherapy and in combination with the PD-1 inhibitor Nivolumab, was assessed against BCa cell lines and autologous PDO through viability (ATP), cytokine release (IFN-γ, ELISA), and apoptosis (caspase 3/7) assays. In vivo validation was performed in a 5637 cell-line-derived xenograft (CDX) mouse model. Results: TIL were successfully expanded from 33 of 48 BCa samples with high yields of viable cells. Expanded TIL were predominantly CD8 + cytotoxic T lymphocytes. Integrated scRNA and TCR-seq analysis revealed that REP enriched for cytotoxic effector clones and reduced regulatory T-cell populations. TIL mediated potent tumor-killing efficacy against BCa cell lines and autologous PDO in vitro and significantly suppressed tumor growth in vivo. Critically, combining TIL with Nivolumab synergistically enhanced tumor cell death in PDO and resulted in near-complete tumor suppression in the CDX model, significantly outperforming TIL monotherapy. Conclusions: TIL isolated from bladder cancer patients can be robustly expanded in vitro into a population enriched with CD8⁺ T cells, which exhibited potent anti-tumor activity across both in vitro and in vivo models. Notably, combining TIL with PD-1 blockade significantly enhanced efficacy, establishing TIL-based adoptive cell therapy as a viable immunotherapeutic strategy for bladder cancer and provide a compelling rationale for the clinical translation of TIL combined with Nivolumab.


  • Multiparametric MRI for assessing residual tumors in patients with muscle-invasive bladder cancer after neoadjuvant treatment: a reliable tool for guiding bladder preservation

    by Qian Cai, Li Tian, Lingmin Kong, Keyi Zhang, Bei Weng, Bin Huang, Yan Guo, Jun-Xing Chen, Huanjun Wang

    Objective To evaluate the clinical utility of multiparametric MRI in differentiating pathological stages (ypT0 vs ypT1–4) in patients with muscle-invasive bladder cancer (MIBCa) following neoadjuvant therapy (NAT). Materials and methods In this double-center cohort study, post-NAT multiparametric MRI in all consecutive patients who underwent surgery after NAT was analyzed. Two experienced radiologists independently evaluated the MRI features obtained after NAT. The post-NAT yT stage was assigned based on T2-weighted diffusion-weighted imaging (T2DWI) and on contrast-enhanced MRI scans. The diagnostic accuracies for distinguishing post-NAT ypT0 from ypT1–4 tumors with the two protocols were evaluated. Cohen’s kappa (κ) statistics were used to evaluate the consistency between readers for the post-NAT yT stage. Results A total of 149 patients (mean age, 62 years ± 10 [SD]; 131 men) from two institutions were enrolled. The area under the receiver operating characteristic curve of the contrast-enhanced MRI protocol in predicting post-NAT ypT0 stage was 0.84 (95% CI: 0.77, 0.91), which was better than that of the T2DWI protocol (0.75; 95% CI: 0.67, 0.81; p = 0.002). The interobserver agreement was excellent for both the T2DWI protocol (κ = 0.89) and the contrast-enhanced MRI protocol (κ = 0.85). Conclusions Multiparametric MRI, particularly contrast-enhanced MRI, demonstrated superior accuracy in identifying ypT0 status following NAT in MIBCa, establishing it as an essential diagnostic tool for guiding bladder preservation in clinical decision-making. Key Points Question Accurately identifying pathological complete response (ypT0) after NAT is essential for selecting bladder-preservation strategies, yet remains clinically challenging. Findings Post-treatment contrast-enhanced MRI accurately identified ypT0 status with an AUC of 0.84 and excellent inter-reader agreement, outperforming T2DWI. Clinical relevance Contrast-enhanced MRI is a reliable, non-invasive method for detecting complete tumor response after NAT, enabling better patient selection for bladder-sparing approaches and potentially improving quality of life. Graphical Abstract


  • Open Access

    Supplementary Data 1 from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

    by Jinwen Liu, Gaowei Huang, Hao Lin, Rui Yang, Wenhao Zhan, Cheng Luo, Yukun Wu, Lingwu Chen, Xiaopeng Mao, Junxing Chen, et al.

    Sunitinib resistant cell RNA_seq data

  • Open Access

    Supplementary Information from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

    by Jinwen Liu, Gaowei Huang, Hao Lin, Rui Yang, Wenhao Zhan, Cheng Luo, Yukun Wu, Lingwu Chen, Xiaopeng Mao, Junxing Chen, et al.

    Figure S1-S17,Table S1-S2,Supplementary methods

  • Open Access

    Supplementary Data 2 from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

    by Jinwen Liu, Gaowei Huang, Hao Lin, Rui Yang, Wenhao Zhan, Cheng Luo, Yukun Wu, Lingwu Chen, Xiaopeng Mao, Junxing Chen, et al.

    Supplementary Data 2 from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma